• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型β-内酰胺/β-内酰胺酶抑制剂复方制剂头孢地尔、普拉佐米星与对照药物对产碳青霉烯酶分离株的活性。

activity of newer β-lactam/β-lactamase inhibitor combinations, cefiderocol, plazomicin and comparators against carbapenemase-producing isolates.

机构信息

Department of Clinical Microbiology and Microbial Pathogenesis, University Hospital of Heraklion, Heraklion, Crete, Greece.

University of Crete Medical School, Heraklion, Crete, Greece.

出版信息

J Chemother. 2023 Nov;35(7):596-600. doi: 10.1080/1120009X.2023.2170906. Epub 2023 Jan 27.

DOI:10.1080/1120009X.2023.2170906
PMID:36705145
Abstract

Infections by carbapenem-resistant (CRKP) remain one of the greatest healthcare threats associated with significant morbidity and mortality. New antimicrobials were recently developed to address this threat. We assessed the epidemiology of carbapenemase-producing (CPKP) isolates recovered in a Greek university hospital during 2021, and their susceptibilities to old and newer antimicrobials. Minimum inhibitory concentrations (MICs) were determined by the MIC Test Strip method, except for cefiderocol (CFDC) and colistin that were evaluated by the broth microdilution method. A total of 110 CPKP strains were isolated, with KPC-producers being the most prevalent (64.6%). Among the agents tested, plazomicin (PL) displayed the highest activity against all the isolates (MIC/MIC, 0.5/1.5 μg/ml), followed by tigecycline (MIC/MIC, 1.5/4 μg/ml). All KPC-producing were susceptible to ceftazidime-avibactam (CAZ/AVI) and meropenem-vaborbactam (M/V) and 97.2% of them to imipenem-relebactam (I/R). Among the MBL-producing isolates, PL and CFDC exhibited the highest activity.

摘要

耐碳青霉烯肠杆菌科(CRKP)感染仍然是与高发病率和死亡率相关的最大的医疗保健威胁之一。最近开发了新的抗生素来应对这一威胁。我们评估了 2021 年希腊一家大学医院分离的产碳青霉烯酶(CPKP)分离株的流行病学情况及其对旧和新抗生素的敏感性。除头孢他啶-阿维巴坦(CAZ/AVI)和美罗培南-维巴坦(M/V)外,最小抑菌浓度(MIC)均采用 MIC 测试条法测定,多粘菌素 E 采用肉汤微量稀释法测定。共分离出 110 株 CPKP 菌株,其中 KPC 产菌株最为常见(64.6%)。在所测试的药物中,帕拉米韦(PL)对所有分离株的活性最高(MIC/MIC,0.5/1.5μg/ml),其次是替加环素(MIC/MIC,1.5/4μg/ml)。所有 KPC 产菌株均对头孢他啶-阿维巴坦(CAZ/AVI)和美罗培南-维巴坦(M/V)敏感,其中 97.2%对亚胺培南-雷巴坦(I/R)敏感。在产金属β-内酰胺酶(MBL)的分离株中,PL 和头孢他啶-阿维巴坦(CAZ/AVI)表现出最高的活性。

相似文献

1
activity of newer β-lactam/β-lactamase inhibitor combinations, cefiderocol, plazomicin and comparators against carbapenemase-producing isolates.新型β-内酰胺/β-内酰胺酶抑制剂复方制剂头孢地尔、普拉佐米星与对照药物对产碳青霉烯酶分离株的活性。
J Chemother. 2023 Nov;35(7):596-600. doi: 10.1080/1120009X.2023.2170906. Epub 2023 Jan 27.
2
Epidemiology and in vitro activity of ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates.希腊产碳青霉烯酶肺炎克雷伯菌分离株的流行病学和头孢他啶-阿维巴坦、美罗培南-法硼巴坦、亚胺培南-雷利巴坦、依拉环素、硫酸普拉米星及对照药物的体外活性
Infection. 2022 Apr;50(2):467-474. doi: 10.1007/s15010-021-01735-1. Epub 2021 Dec 2.
3
In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015-2016.2015-2016 年在希腊医院分离的产非 MBL 碳青霉烯酶肺炎克雷伯菌的亚胺培南-雷利巴坦体外活性。
Eur J Clin Microbiol Infect Dis. 2019 Jun;38(6):1143-1150. doi: 10.1007/s10096-019-03517-y. Epub 2019 Mar 1.
4
Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam.头孢他啶-阿维巴坦对产 KPC-2 的肠杆菌科的抗菌活性:雷巴他定和沃巴他定联合用药及剂量递增滴定研究。
Microbiol Spectr. 2024 Jun 4;12(6):e0034424. doi: 10.1128/spectrum.00344-24. Epub 2024 Apr 30.
5
Susceptibility evaluation of novel beta-lactam/beta-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in hospitalized patients in Brazil.巴西住院患者血流感染碳青霉烯类耐药肺炎克雷伯菌的新型β-内酰胺/β-内酰胺酶抑制剂组合的药敏评估。
J Glob Antimicrob Resist. 2024 Sep;38:247-251. doi: 10.1016/j.jgar.2024.06.007. Epub 2024 Jun 25.
6
Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa.新型β-内酰胺/β-内酰胺酶抑制剂联合制剂对产丝氨酸碳青霉烯酶的碳青霉烯类耐药铜绿假单胞菌的活性。
J Antimicrob Chemother. 2023 Dec 1;78(12):2795-2800. doi: 10.1093/jac/dkad225.
7
In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects.头孢地尔在体外对头孢他啶-阿维巴坦敏感和耐药的产 KPC 肠杆菌科的活性:交叉耐药性和协同作用。
Eur J Clin Microbiol Infect Dis. 2022 Jan;41(1):63-70. doi: 10.1007/s10096-021-04341-z. Epub 2021 Aug 31.
8
In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates.头孢他啶-阿维巴坦与不同抗菌药物联合对产KPC肺炎克雷伯菌临床分离株的体外相互作用
Int J Infect Dis. 2017 Dec;65:1-3. doi: 10.1016/j.ijid.2017.09.017. Epub 2017 Sep 22.
9
Mechanisms of Resistance Development to Imipenem-Relebactam in KPC-Producing Klebsiella pneumoniae.产碳青霉烯酶肺炎克雷伯菌对亚胺培南-雷巴坦耐药机制的研究。
Antimicrob Agents Chemother. 2022 Oct 18;66(10):e0091822. doi: 10.1128/aac.00918-22. Epub 2022 Sep 26.
10
Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.中国耐碳青霉烯类肺炎克雷伯菌中头孢他啶/阿维巴坦耐药的出现。
Clin Microbiol Infect. 2020 Jan;26(1):124.e1-124.e4. doi: 10.1016/j.cmi.2019.08.020. Epub 2019 Sep 5.

引用本文的文献

1
Breaking Through Resistance: A Comparative Review of New Beta-Lactamase Inhibitors (Avibactam, Vaborbactam, Relebactam) Against Multidrug-Resistant Superbugs.突破耐药性:新型β-内酰胺酶抑制剂(阿维巴坦、瓦博巴坦、瑞来巴坦)抗多重耐药超级细菌的比较综述
Antibiotics (Basel). 2025 May 21;14(5):528. doi: 10.3390/antibiotics14050528.
2
Outbreak of High-Risk Clone ST323 Resistant to Ceftazidime-Avibactam Due to Acquisition of and to Cefiderocol Due to Mutated Gene.因获得blaOXA-181基因而对头孢他啶-阿维巴坦耐药且因mcr-1基因变异而对头孢地尔耐药的高危克隆ST323暴发。
Antibiotics (Basel). 2025 Feb 21;14(3):223. doi: 10.3390/antibiotics14030223.
3
Insights into the Rising Threat of Carbapenem-Resistant Enterobacterales and Epidemic Infections in Eastern Europe: A Systematic Literature Review.
东欧耐碳青霉烯类肠杆菌科细菌及流行感染日益严重威胁的洞察:一项系统文献综述
Antibiotics (Basel). 2024 Oct 17;13(10):978. doi: 10.3390/antibiotics13100978.
4
Characterization of and Plasmids of a ST11 Outbreak Clone.ST11暴发克隆株的质粒特征及[相关内容未完整给出,无法准确翻译]质粒
Antibiotics (Basel). 2023 May 18;12(5):926. doi: 10.3390/antibiotics12050926.
5
Iron Acquisition and Metabolism as a Promising Target for Antimicrobials (Bottlenecks and Opportunities): Where Do We Stand?铁的获取和代谢作为抗菌药物的有前途的靶点(瓶颈和机遇):我们处于什么位置?
Int J Mol Sci. 2023 Mar 24;24(7):6181. doi: 10.3390/ijms24076181.